...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Report Of Exempt Distribution.

Assuming that the $500K (secured) promissory note is coming from Don, which may go to fund Resverlogix, you have to ask why the Promossry note is not directed straight to Resverlogix. 

Zenith provides Don with more security than Resverlogix can offer, seeing that the HL Debenture holds security offer RVX's Intellectual Properties.

Resverlogix has not seen funding outside Zeniths since May 23, 2023. 

Not sure what to make of it ... Koo

 

Share
New Message
Please login to post a reply